SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.

Guardado en:
Detalles Bibliográficos
Autores principales: Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/63c728d50eef448aa2fdb9117a059704
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.

Ejemplares similares